Aurobindo says it is continuing to focus its efforts on driving profitability through a “differentiated portfolio”, with a particular focus on dermatology, after striking in early September a US$1.0 billion deal to acquire Sandoz’ dermatology and oral-solids business in the US.
Aurobindo says it is continuing to focus its efforts on driving profitability through a “differentiated portfolio”, with a particular focus on dermatology, after striking in early September a US$1.0 billion deal to acquire Sandoz’ dermatology and oral-solids business in the US.
“On our differentiated portfolio front, we have filed two abbreviated new drug applications (ANDAs) in dermatology and one nasal ANDA...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
